Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2021-12-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于股价异动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock price fluctuations of the company 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It details the stock price movements over specific dates, the company's investigation into the cause, confirmation of no undisclosed material information, and a risk warning to investors. It also references the upcoming annual report disclosure date but does not contain any financial statements or detailed financial data itself. The document is short (1441 characters) and serves as a regulatory disclosure about stock price abnormality rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-28 Chinese
关于控股股东进行约定购回式证券交易购回的公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from a company regarding a transaction involving its controlling shareholder conducting a repurchase of shares through an agreed repurchase securities transaction. It details the shareholding changes before and after the transaction, the nature of the transaction, compliance with relevant laws and regulations, and confirms no change in control or adverse impact on governance. The document is relatively short (2415 characters) and focuses on a specific shareholding transaction rather than financial results, management changes, or legal proceedings. It does not contain financial statements or earnings data, nor is it a report or presentation. The content fits the category of a Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares.
2021-12-10 Chinese
康芝药业独立董事关于第五届董事会第二十一会议相关议案的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion from the independent directors of 康芝药业股份有限公司 regarding the termination of a specific share issuance proposal at the 21st meeting of the 5th board. It references legal and regulatory frameworks and confirms the board's compliance and decision. The document is short (591 characters) and focuses on board opinions about a capital issuance matter, not the issuance itself or detailed financial data. This fits best under Board/Management Information (MANG) as it relates to board decisions and opinions on corporate actions, rather than a full capital/financing update or regulatory filing. Confidence is high due to clear context and content.
2021-11-23 Chinese
关于终止向特定对象发行A股股票事项的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 康芝药业股份有限公司 regarding the termination of a previously planned issuance of A shares to specific investors. It details the board and supervisory committee meetings where the termination was approved, the reasons for termination, and the impact on the company. The document does not contain financial statements or detailed financial data but is a formal disclosure of a corporate decision related to capital raising activities. This fits the category of a Capital/Financing Update (CAP) as it informs about changes in the company's financing plans rather than the issuance itself or a full financial report.
2021-11-23 Chinese
第五届监事会第十七次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. regarding the termination of a specific share issuance plan (termination of a private placement of A shares). It includes voting results and a statement that the decision was made in compliance with laws and company articles. The document references a separate announcement about the termination of the share issuance. The content is about a board/committee decision on capital raising activities but does not itself constitute a detailed capital/financing update report. It is a formal announcement of a board resolution related to capital issuance. Given the nature of the content, it fits best under Capital/Financing Update (CAP) as it concerns financing activities and capital structure changes. The document length is short and focused on a specific financing decision, not a full report or regulatory filing. Therefore, the classification is CAP with high confidence.
2021-11-23 Chinese
康芝药业独立董事关于第五届董事会第二十一次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the pre-approval of a board meeting agenda item about terminating a specific share issuance. It references company law, securities law, and stock exchange rules, indicating a governance-related matter. The content is about board meeting agenda approval and independent directors' opinions, not a full report or financial statement. The document length is short (601 characters), and it is a statement related to board/management decisions rather than a financial report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG).
2021-11-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.